Veri Medtech Holdings, Inc. (VRHID) is conducting a firm-commitment public offering of 3,750,000 shares of common stock at an assumed price of $4.00 per share, for expected gross proceeds of $15.0 million, conditional on approval for listing on the NASDAQ Capital Market under the symbol VRHI.
The company is a holding company whose main business, via subsidiary Veriheal, is providing technology-enabled concierge services that help patients obtain and renew medical marijuana cards across numerous U.S. states, plus related cannabis consultation services. It generated approximately $11 million of revenue in 2025 and $17 million in 2024 from medical marijuana card services, but reported net losses of about $2.32 million and $0.41 million, respectively, and its auditors highlight substantial doubt about its ability to continue as a going concern.
As of September 22, 2026, there were 8,000,004 shares outstanding, expected to increase to 11,750,004 after the offering (excluding the underwriter’s overallotment). Executives control the company through Series A Preferred Stock representing 80% of voting power, so it will qualify as a NASDAQ “controlled company,” though it states it will follow full corporate governance requirements. The company effected a 1-for-2.5 reverse stock split on September 2, 2026, has a 3,000,000-share stock repurchase program, and qualifies as an emerging growth company and smaller reporting company, using scaled disclosure. Extensive risk factors emphasize its limited operating history, ongoing losses, going-concern uncertainties, dependence on online advertising and cannabis-related regulations, and execution risks in marketing, technology, and potential acquisitions.
Veri MedTech Holdings, Inc. (VRHID) is conducting a firm-commitment public offering of 3,750,000 shares of Common Stock at an assumed price of $4.00 per share, for expected gross proceeds of $15.0 million, conditional on approval for listing on the NASDAQ Capital Market under the symbol “VRHI.”
After underwriting discounts, a 2% corporate finance fee and other offering expenses, the company expects net proceeds of about $11.95 million, to fund organic and acquisitive growth. Shares outstanding are expected to be 11,750,004 after the offering, excluding any exercise of the 45‑day over-allotment option for up to 562,500 additional shares.
The company operates a healthcare technology platform focused on medical cannabis services and reported 2025 revenue of approximately $11 million and a net loss of about $2.32 million, with auditors highlighting substantial doubt about its ability to continue as a going concern given stockholders’ and working capital deficits.
Veri MedTech Holdings, Inc. (VRHID) is pursuing a NASDAQ Capital Market uplisting via a firm-commitment IPO of 3,750,000 shares of common stock at an assumed price of $4.00 per share, with closing conditioned on NASDAQ approval. The company currently trades on the OTC market under “VRHI.”
Veri MedTech is a holding company whose main business, through subsidiary Veriheal, is a telehealth-style platform that helps patients obtain and renew medical cannabis cards in numerous U.S. states, charging roughly $100–$200 per card and renewal. Revenue was about $11 million in 2025 and $17 million in 2024, with net losses of $2.32 million and $0.41 million, respectively; first-half 2026 revenue was $4.48 million with a net loss of $0.50 million.
The company qualifies as an emerging growth company and smaller reporting company and has implemented a 1‑for‑2.5 reverse stock split effective September 2, 2026. Executives hold all Series A preferred stock, which carries 80% of voting power, making Veri MedTech a controlled company. Auditors highlight substantial doubt about its ability to continue as a going concern due to shareholders’ deficit, working-capital deficit, and recurring losses. Net proceeds of roughly $11.95 million are earmarked for organic and acquisitive growth and general corporate purposes.